Abrdn Life Sciences Investors (NYSE:HQL) Sees Large Drop in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 33,800 shares, a decline of 54.4% from the November 15th total of 74,100 shares. Based on an average daily trading volume, of 75,400 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

Institutional investors have recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new stake in Abrdn Life Sciences Investors in the third quarter worth approximately $30,000. Ashton Thomas Securities LLC bought a new position in shares of Abrdn Life Sciences Investors in the third quarter valued at $148,000. Kapstone Financial Advisors LLC bought a new position in shares of Abrdn Life Sciences Investors in the third quarter valued at $177,000. Sanctuary Advisors LLC bought a new position in shares of Abrdn Life Sciences Investors in the second quarter valued at $154,000. Finally, Stephens Inc. AR increased its holdings in shares of Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after buying an additional 896 shares in the last quarter. 32.21% of the stock is currently owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Stock Performance

HQL traded down $0.14 during trading on Friday, reaching $13.84. The stock had a trading volume of 73,123 shares, compared to its average volume of 92,054. Abrdn Life Sciences Investors has a 1-year low of $12.76 and a 1-year high of $15.90. The stock has a 50 day moving average of $14.58 and a two-hundred day moving average of $14.70.

Abrdn Life Sciences Investors Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 14.45%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.